Results

1–10 of 50 results for Phase 3

IL-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Phase 3 MEERKAT and SANDCAT Trials
Anat Loewenstein, MD
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor-Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Annual Meeting Talks
2024
Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2024
Baseline Ellipsoid Zone Integrity Features as Predictors of Geographic Atrophy Growth Rate in the Phase 3 GATHER Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Updates from the Field
2024
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Annual Meeting Talks
2022